|
|
500 Kendall Street
Cambridge, MA 02142
phone:617 252 7500
fax:617 252 7600
|
|
| Symbol |
GENZ |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
|
|
|
| www.anormed.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Small molecule therapeutics for the treatment of HIV, inflammation and cancer. |
|
| Management |
| Henri A. Termeer, Chairman of the Board, President, and Chief Executive Officer; Douglas A. Berthiaume, Chair Audit Committee, Compensation Committee Member, Nominating/Governance Committee Member; Henry E. Blair; Gail K. Boudreaux, Audit Committee Member, Nominating/Governance Committee Member; Robert J. Carpenter; Charles L. Cooney, Ph.D., Chair Compensation Committee, Nominating-Governance Committee Member; Victor J. Dzau, M.D., Compensation Committee Member, Nominating/Governance Committee Member; Senator Connie Mack III, Chair Nominating/Governance Committee, Audit Committee Member; Richard F. Syron,
Audit Committee Member, Nominating/Governance Committee Member |
| |
|
|
|
|
|
|
|
| Keywords |
| hiv, hematology, oncology, cancer, inflammation, small molecule, HIVAIDS |
|
|
|
| Description |
|
AnorMED's core strength involves the application of chemistry, biochemistry and biology to the discovery and development of small molecule therapeutics for the treatment of diseases including HIV, inflammation and cancer. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
